Wave Life Sciences (WVE) Non-Current Assets (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Non-Current Assets came in at $50.8 million in Q2 2026, up 76.44% YoY from $28.8 million in Q2 2025, and up 128.15% on a QoQ basis from $22.3 million in Q1 2026.
Wave Life Sciences (WVE) Non-Current Assets (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Non-Current Assets data on file, last reported at $50.8 million in Q2 2026.
- Quarterly Non-Current Assets rose 76.44% year-over-year to $50.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $50.8 million (up 76.44% YoY) and the FY2025 annual result came in at $23.7 million, down 25.55% from the prior year.
- Non-Current Assets grew to $50.8 million in Q2 2026, from $22.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $53.2 million in Q2 2022 to a low of $22.3 million in Q1 2026.
- A 5-year average of $38.4 million and a median of $39.0 million in 2023 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 76.44% in 2026, down 26.66% in 2026.
- Tracing WVE's Non-Current Assets over 5 years: stood at $47.8 million in 2022, then declined by 17.29% to $39.6 million in 2023, then dropped by 19.62% to $31.8 million in 2024, then fell by 25.55% to $23.7 million in 2025, then soared by 114.54% to $50.8 million in 2026.
- The last three Non-Current Assets figures came in at $50.8 million (Q2 2026), $22.3 million (Q1 2026), and $23.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | 50.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.81 Mn |
| Mar 31, 2026 | 22.27 Mn |
| Dec 31, 2025 | 23.69 Mn |
| Sep 30, 2025 | 25.89 Mn |
| Jun 30, 2025 | 28.80 Mn |
| Mar 31, 2025 | 30.37 Mn |
| Dec 31, 2024 | 31.81 Mn |
| Sep 30, 2024 | 33.99 Mn |
| Jun 30, 2024 | 36.74 Mn |
| Mar 31, 2024 | 38.50 Mn |
| Dec 31, 2023 | 39.58 Mn |
| Sep 30, 2023 | 41.35 Mn |
| Jun 30, 2023 | 45.28 Mn |
| Mar 31, 2023 | 47.68 Mn |
| Dec 31, 2022 | 47.85 Mn |
| Sep 30, 2022 | 50.08 Mn |
| Jun 30, 2022 | 53.21 Mn |
| Mar 31, 2022 | 42.98 Mn |
| Dec 31, 2021 | 44.44 Mn |
| Sep 30, 2021 | 42.53 Mn |